

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**

License number 13-17129-01

Docket or Reference number
030-12236

Amendment No. 04

Whitley County Memorial Hospital
353 N. Oak Street
Columbia City, IN 46725

In accordance with letter dated November 15, 1985, License Number 13-17129-01 is amended as follows:

Conditions 12. and 19. are amended to read:

12. Licensed material listed in Item 6 above is authorized for use by, or under the supervision of, the following individual(s) for the materials and uses indicated:

James M. Rausch, M.D.

Groups I, II, III and IV

Thomas G. Armbuster, M.D.

Groups I, II and III

Thomas J. Hicks, M.D.

Groups I, II and III
Phosphorus-32 for treatment of
polycythemia vera, leukemia
and bone metastases

William L. Bridges, M.D.

Groups I, II and III
Phosphorus-32 for treatment of
polycythemia vera, leukemia
and bone metastases

Robert D. Dormire, M.D.

Groups I, II and III
Phosphorus-32 for treatment of
polycythemia vera, leukemia
and bone metastases

Phillip D. Godsey, M.D.

Groups I, II and III
Phosphorus-32 for treatment of
polycythemia vera, leukemia
and bone metastases
Iodine-131 for treatment of
hyperthyroidism and cardiac
dysfunction

Donald R. Sugarman, M.D.

Groups I, II and III
Phosphorus-32 for treatment of
polycythemia vera, leukemia
and bone metastases

8602200009 851216
REG3 LIC30
13-17129-01 PDR

COPY 2
11/16/85

MATERIALS LICENSE
SUPPLEMENTARY SHEET

License number 13-17129-01

Docket or Reference number 030-12236

Amendment No. 04

Richard L. Jontz, M.D.

Groups I, II and III
Phosphorus-32 for treatment of
polycythemia vera, leukemia
and bone metastases

Marc E. Kaminski, M.D.

Groups I, II and III

William D. Zimmer, M.D.

Groups I, II and III

Ray W. Gize, M.D.

Groups I, II, III and IV

Harold R. Griffith, M.D.

Groups I, II, III and IV

19. Except as specifically provided otherwise by this license, the licensee shall possess and use licensed material described in Items 6, 7, and 8 of this license in accordance with statements, representations, and procedures contained in applications dated November 19, 1981 and July 23, 1982; letter dated November 29, 1985; and Model ALARA Program as contained in Appendix O of Regulatory Guide 10.8, October 1980. The Nuclear Regulatory Commission's regulations shall govern the licensee's statements in applications or letters, unless the statements are more restrictive than the regulations.



For the U.S. Nuclear Regulatory Commission

Date DEC 16 1985

Original Signed
By Evelyn R. Matson
Materials Licensing Section, Region III

COPY